The Impact of Vitamin D Deficiency on the Severity of Symptoms and Mortality Rate among Adult Patients with Covid-19: A Systematic Review and Meta-Analysis

Maisa Hamed Al Kiyumi, Sanjay Kalra1, J.S. Davies2, Atul Kalhan3
Department of Family Medicine and Public Health, Sultan Qaboos University Hospital, Muscat, Oman, 1Department of Endocrinology, Bharti Hospital, Karnal, India, 2Department of Endocrinology, University Hospital of Wales, Cardiff, 3Department of Diabetes and Endocrinology, Royal Glamorgan Hospital, Wales, UK

Abstract

Introduction: We aimed to study the prevalence of vitamin D deficiency (VDD) in patients with COVID-19 infection and evaluate the impact of vitamin D levels on the severity of symptoms and the case fatality rate. Evidence Acquisition: A comprehensive literature search was performed up to December 20, 2020, using the following databases: MEDLINE, PubMed, EMBASE, SCOPUS, Web of Science, and preprint databases (BioRxiv and MedRxiv). Any individual observational study related to the prevalence and impact of vitamin D deficiency/insufficiency (VDD/VDI) on the severity of COVID-19 symptoms and mortality rates was included. No language restrictions were applied, and both published and non-published studies were included. Evidence Synthesis: Two of the authors independently performed the literature search and assessed the eligibility of studies. The quality of studies included was assessed using the Newcastle-Ottawa Scale. Data were analyzed using the Review Manager Software (version 5) and Comprehensive Meta-analysis Software (version 3). A total of 43 studies were included with a sample size of 254,963 patients with COVID-19. Pooled analysis showed a higher prevalence of VDD and VDI in patients with COVID-19 (59.0% and 40.1%, respectively). Moreover, a significant association was noticed between vitamin D levels and severity of symptoms (odds ratio [OR] = 3.38, 95% confidence interval [CI]: 1.94–5.87, \( P < 0.0001 \)), as well as the case fatality rate (OR = 2.30, 95% CI: 1.47–3.59, \( P < 0.00001 \)). Conclusions: VDD is highly prevalent in patients with COVID-19 infection. Lower vitamin D levels correlate with disease severity and poor prognosis although most of the data have been derived from moderate-quality observational studies.

Keywords: Vitamin D; 25-hydroxyvitamin D; 25-OH vitamin D; coronavirus; COVID-19

INTRODUCTION

There has been renewed interest in the possible role of vitamin D in the prevention and treatment of acute respiratory infection in light of the ongoing COVID-19 pandemic. 1,25-hydroxyvitamin D, the active metabolite of vitamin D, is produced in the kidneys via hydroxylation of the inactive form, 25-hydroxyvitamin D.\(^1\) 1,25-hydroxyvitamin D exerts its actions by binding to vitamin D receptors (VDRs) that are nuclear, ligand-dependent transcription factors involved in the regulation of over 900 genes essential for maintaining a wide array of physiological functions.\(^1\)

Active metabolites of vitamin D have been shown to stimulate innate as well as acquired immune responses.\(^2,3\) Evidence derived from experimental studies suggests 1,25-hydroxyvitamin D levels have an inverse correlation with pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor \( \alpha \) (TNF\( \alpha \)), which are the key inflammatory markers linked to the development of adult respiratory distress syndrome (ARDS).\(^4,5\) The vitamin D-induced upregulation of cathelicidins and \( \beta \) defensins, which are potent antimicrobial peptides, is considered to be an important factor in mitigating the severity of acute respiratory infections.\(^6\)

Address for correspondence: Dr. Maisa Hamed Al Kiyumi,
Sultan Qaboos University Hospital, P.O. Box 35, PC.123,
Al-Khod, Muscat, Sultanate of Oman, Oman.
Email: maysa8172@gmail.com

Submitted: 12-Mar-2021
Accepted: 20-Oct-2021
Published: 15-Dec-2021

How to cite this article: Al Kiyumi MH, Kalra S, Davies JS, Kalhan A. The impact of vitamin D deficiency on the severity of symptoms and mortality rate among adult patients with COVID-19: A systematic review and meta-analysis. Indian J Endocr Metab 2021;25:261-82.
The biological plausibility of the immunomodulatory role of vitamin D can be extrapolated as one of the important causal factors linked to an increased incidence of acute respiratory tract infections in geographic regions with vitamin D deficiency (VDD) or vitamin D insufficiency (VDI), especially during the winter months. There is also a higher prevalence rate of VDD in the elderly, obese, darker skin ethnicities, and hospitalized patients, with these factors emerging as strong predictors of adverse clinical outcomes in patients with COVID-19.

A number of epidemiological and observational studies have reported an inverse correlation between vitamin D levels and COVID-19 severity and case-fatality rates. Besides, the seasonal dependence of the COVID-19 pandemic indicates an inverse correlation with solar ultraviolet dose and thereby vitamin D production. One of the ecological studies has underlined higher rates of COVID-19 cases and deaths in countries such as Italy and Spain, which have an overall lower mean concentration of 25-hydroxyvitamin D. In contrast, countries, such as Finland and Norway, which have implemented a vitamin D food fortification policy, have reported a significantly lower number of COVID-19 cases and deaths.

An analysis of 186 patients with COVID-19 confirmed an inverse correlation between vitamin D levels and disease severity based on radiological findings. A similar finding was confirmed by another large retrospective population-based study that substantiated a 1.6% lower risk for SARS-CoV-2 positivity with each increment of 1 ng/mL of vitamin D level. In contrast, a study based on participants recruited from the UK Biobank did not observe any association between VDD and the risk of developing COVID-19 in a multivariate analysis. However, these findings might be influenced by the fact that the COVID-19 polymerase chain reaction (PCR) test results were available only in 1,474 of the 348,598 individuals recruited, resulting in underestimation of the true prevalence of COVID-19 in this cohort. In addition, the results of this study need to be interpreted cautiously, as the baseline vitamin D levels of biobank participants were measured over a decade ago (2006–2010).

A meta-analysis of 11,321 participants supported the benefit of vitamin D supplements in preventing acute respiratory tract infections, although uncertainty exists about the generalization of these observations to patients with COVID-19 as well. Overall, it is biologically plausible that active metabolites of vitamin D levels have an impact on COVID-19 disease severity although the evidence that has emerged so far from observational studies has been conflicting and of moderate quality.

We have carried out this systematic review and meta-analysis to ascertain the prevalence of VDD in patients with COVID-19. We have also evaluated whether there is any correlation between vitamin D levels with disease severity and case-fatality rate in adult patients with COVID-19.

**Evidence acquisition**

**Study design**

A systematic review and meta-analysis of observational studies (cross-sectional, cohort, case-control studies, and case series) related to the prevalence of VDD/VDI in patients with COVID-19 and the association of low vitamin D levels with disease severity and mortality rates in patients with COVID-19 were conducted. The PRISMA guidelines were followed in this study. This systematic review is registered at PROSPERO NIH; registration number is CRD42020196502.

**Search strategy**

A literature search was conducted using the following databases: MEDLINE, PubMed, EMBASE, SCOPUS, Web of Science, and preprint databases (BioRxiv and MedRxiv). Moreover, manual searching for references that were cited in the retrieved articles was performed and the authors were contacted if deemed necessary. The literature search was carried out until December 20, 2020. Search terms included “Vitamin D” or “25-hydroxyvitamin D” or “25-OH vitamin D” and “coronavirus” or “SARS-CoV-2” or “COVID-19.”

**Inclusion and exclusion criteria**

Inclusion criteria included i) any individual observational studies (prospective or retrospective) related to the prevalence and impact of VDD/VDI on the symptoms severity of COVID-19 and mortality rates, ii) adult human studies, and iii) published and unpublished. Notably, no language restrictions were applied in this review.

Exclusion criteria included i) in vitro studies, ii) experimental studies, iii) ecological studies, review articles, case reports, and editorial articles unless they contain information relevant to the unpublished studies, and iv) studies performed on the pediatric population.

**Primary outcomes**

The three primary outcomes in the current review include i) the prevalence of VDD/VDI in patients with COVID-19, measured by determining the number of events in three sub-groups: subgroup A: VDD <20 ng/mL, subgroup B: VDI: 20–30 ng/mL, and subgroup C: normal vitamin D ≥30 ng/mL) in patients with COVID-19; ii) the severity of COVID-19, which is defined by the number of patients with COVID-19 (3 subgroups: A: VDD, B: VDI, and C: normal range) who required admission to intensive care units (ICU) and/or required invasive oxygen therapy or ventilatory support or developed acute respiratory distress syndrome (ARDS) or severe radiological changes; and iii) the case-fatality rate, measured by dividing the number of deaths that occurred in recruited participants by the total sample size.

**Data extraction**

Two of the authors independently performed the literature search (title and abstract) and assessed the eligibility of studies. Studies that fulfilled the inclusion criteria were included in the current systematic review. Any disagreements between the assessments were resolved by consensus.
The following data were retrieved from the eligible studies: author names and year of publication, country, study design, sample size, the mean age of recruited subjects, the cut-off value of VDD/VDI, odds ratio (OR) for dichotomous data, and mean for continuous variables, confidence intervals, \(P\) value, and summary of findings. Notably, any adjustment for confounders (i.e., comorbidities) was reported.

Quality assessment

Two of the authors independently evaluated the quality of included studies using the Newcastle–Ottawa Scale (NOS) for case–control and cohort studies.\(^{[19]}\) Moreover, the modified NOS was used to assess the quality of cross-sectional studies.\(^{[20]}\) NOS is a reliable and validated tool that assesses three essential parameters of observational studies: selection, comparability, and outcome ascertainment.\(^{[19]}\) It is scored from 0 to 9 for case–control and cohort studies and 0 to 10 for cross-sectional studies. Generally, a score of less than 5 indicates a high risk of bias. Any disagreement between the authors was resolved by consensus.

Evidence synthesis

Statistical analysis

Data from the meta-analysis were analyzed using the Review Manager Software (version 5) and Comprehensive Meta-analysis Software (version 3). Pooled data were presented as the events rate for the prevalence of VDD/VDI in patients with COVID-19 and the OR was reported for the association between VDD/VDI and disease severity and mortality. Findings that were reported as the median and interquartile range in some of the included studies were converted to the mean and standard deviation and another pooled analysis of mean vitamin D level (ng/mL) and severity of symptoms of COVID-19 was produced.\(^{[21]}\) A \(P\) value of less than 0.05 was considered statistically significant. Sensitivity analysis was performed to evaluate the effects of individual studies on overall pooled results and heterogeneity. Furthermore, publication bias was assessed using the funnel plot and Egger’s regression intercept.

Heterogeneity between studies was assessed using the \(I^2\) statistics. A value of >25% indicates considerable heterogeneity between studies. The random-effects model was used in the current analysis in view of a wide range of studies included and we intended to generalize the findings beyond the current sample.\(^{[22]}\)

Ethical approval

The work was completed in partial fulfilment of an MSc in endocrinology from the University of South Wales, UK.

Results

Following a thorough search in the aforementioned databases, 7,106 references were initially retrieved, of which 63 studies were eligible after removing the duplicates and reviewing the titles and abstracts. Forty-three studies were included in the systematic review after full-text assessment (39 were published studies and 4 studies were at a preprint stage).\(^{[23-26]}\) Figure 1 depicts the PRISMA flow diagram of study selection. The sample size of the studies included ranged from 10 to 191,779, with 254,963 participants with COVID-19. For the meta-analysis, studies conducted in the UK Biobank\(^{[13,16,23-26,27]}\) were excluded because vitamin D testing was performed a decade ago. Additionally, other studies that included patients with VDD who were tested during the preceding 5 to 10 years prior to COVID-19 diagnosis were excluded from the meta-analysis.\(^{[28,29]}\) Twenty-nine studies addressed the prevalence of VDD/VDI in patients with COVID-19, whereas 17 studies identified the association between VDD/VDI and severity of symptoms and mortality rate. Table 1 summarizes the characteristics of studies included in the systematic review.

Prevalence of VDD/VDI in patients with COVID-19

There were different cut-off values for VDD and VDI among the recruited studies. A cut-off value <20 ng/mL was used to define vitamin D deficiency in the majority of studies,\(^{[13,14,31,33,34,36,38,39,41,43,44,46-48,53,54,57,58,63]}\) whereas vitamin D deficiency was defined in five studies\(^{[36,39,46,48,61]}\) if the level was <30 nmol/L, which is equivalent to 12 ng/mL and <25 nmol/L in another study.\(^{[56]}\) Moreover, Lau et al. (2020),\(^{[25]}\) Maghbbooli et al. (2020),\(^{[45]}\) Ferrari et al. (2020),\(^{[51]}\) and Abdollahi et al. (2020)\(^{[55]}\) used a cut-off value <30 ng/mL to define VDI, which therefore also included those with VDD. For the sake of this meta-analysis, we included these studies in the insufficiency group. Furthermore, Radujkovic et al. (2020),\(^{[39]}\) Panagiotou et al. (2020),\(^{[42]}\) and Pizinni (2020)\(^{[52]}\) defined VDI as a level <50 nmol/L, which is equivalent to <20 ng/mL. For consistency with other studies, we categorized this cut-off value as VDD. In addition, the study conducted by D’Avolio et al. (2020)\(^{[50]}\) did not report any event rates of VDD/VDI among patients with COVID-19, and data were presented by inter-quartile range. However, the author was contacted via email and the events rate was provided. Also, Abrishami et al. (2020)\(^{[35]}\) defined VDD if the level is less than 25 ng/mL. Lastly, the cut-off value to define VDD was not mentioned in the two studies and therefore excluded from the meta-analysis.\(^{[28,29]}\) With the exception of a study conducted by Meltzer et al. (2020),\(^{[53]}\) no studies accounted for the possibility of vitamin D treatment initiation or adjustment after testing in defining VDD/VDI. Meltzer et al. (2020)\(^{[53]}\) labeled patients as likely to be vitamin D deficient if they had low vitamin D (<20 ng/mL) and there was no increase in the dose of vitamin D treatment after testing. Although observational studies on the pediatric population were excluded from the current analysis, recruited individuals in a population study by Merzon et al. (2020)\(^{[40]}\) ranged in age from 2 months to 103 years. However, only a minority (6%) were aged between 0 and 20 years and we believe that such a low percentage will not affect our findings. Similarly, 4% of recruited participants were under the age of 18 years in another study.\(^{[28]}\) Furthermore, SARS-CoV-2 PCR testing was performed to confirm COVID-19 in the majority of the studies with the exception of one study that identified the association
between VDD and positive seroconversion of COVID-19. For the sake of consistency in the method used to diagnose COVID-19, this study was excluded from our meta-analysis. The pooled analysis underlined a higher prevalence of VDD and VDI in patients with COVID-19 (59.0% and 40.1%, respectively). Figure 2 shows the forest plot of the events rate of VDD/VDI in patients with COVID-19.

**VDD/VDI and the severity of symptoms (outcomes) in patients with COVID-19**

Two analyses were carried out to determine the association between VDD/VDI and severe outcomes in patients with COVID-19. Subjects were divided into the following groups: 1a) COVID-19 and VDD (ordinary outcome/mild), 1b) COVID-19 and VDI (severe outcome), 2a) COVID-19 and VDI (ordinary outcome/mild), 2b) COVID-19 and VDI (severe outcome).

Considerable differences were found when defining the criteria of the severity of COVID-19 within the included studies. As mentioned above, any patients with COVID-19 who developed ARDS, severe radiological changes, or required ICU admission or invasive oxygen therapy or ventilator support, were considered to have severe COVID-19. Smet et al. (2020) determined the association between VDD and severity of COVID-19 using radiological changes on computed tomography (CT) chest. Patients were sub-categorized into three groups, with the third group indicating a more progressive and advanced stage. In our meta-analysis, group three was considered a severe outcome, whereas group one was included under the ordinary/mild category. Similarly, Abrishami et al. (2020) used the radiological worsening of the lungs as an indicator of severe outcome. Also, in studies conducted by Carpagnano et al. (2020) and Kerget et al. (2020), patients who developed ARDS or were admitted to an ICU, respectively, were analyzed under severe outcomes. In a study conducted by Baktash et al. (2020), patients who required ventilator support and a high dependency unit admission were included in the severe category. Finally, in a study conducted by Karonova et al., the authors were contacted for more information regarding the criteria used to define severe cases of COVID-19 and it was stated that severe cases were those who were admitted to the ICU. In accordance with the definition of severe outcome in the present study and given the inadequate information about the severity of COVID-19 among hospitalized patients in a population-based study conducted by Merzon et al. (2020), the hospitalization rate was not considered as a severe outcome and not included in the current analysis. Besides, only 31.06% of recruited subjects had SARS-CoV-2 PCR testing in a study conducted by Maghbooli et al. (2020), which might have affected the estimation of the prevalence of VDD and VDI.
Table 1: Characteristics of studies included in the systematic review

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|------------------|----------------------|-----------------------------------------------|-----------|---------------------|-----------------------|
| Hastie et al[15]         | UK Biobank | Retrospective cross-sectional analysis | 348,598 (449 with COVID-19, 348,149 without COVID-19) | Age range: 37-73 years | -Diabetes: 18874 (5.4%), obesity: 82,928 (23.8%) | VDD: 25(OH) D <25 nmol/L. Time: 2006-2010. Method: immunoassay (Diasorin) | 0.92 (0.71-1.21), P=0.564 (multivariate analysis) | No significant association between vitamin D concentration and COVID-19 risk | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| Hastie et al[16]         | Retrospective cross-sectional analysis | 341,484 participants (656 with COVID-19, 203 deaths) | Age range: 37-73 years | VDD: 25(OH) D <25 nmol/L. Time: 2006-2010. Method: immunoassay (Diasorin) | Vitamin D level and mortality rate: univariate analysis: HR 0.92; 95% CI 0.86-0.98; P=0.016. Multivariate analysis: HR 0.98; 95% CI=0.91-1.06; P=0.696 | No significant association between VD concentration and COVID-19 severity and mortality rate | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| Darling et al[23]        | Preprint | Retrospective analysis | 1303 (580 with COVID-19, 723 without COVID-19) | COVID-19 positive: 57.5 (±8.7). COVID-19 negative: 57.9 (±8.7) | Obesity: n=458 (36.2%) | *Used quartile rather than individual vitamin D level. Q1: bottom 25%, Q2, Q3, Q4: top 25%. Time: 2006-2010. Method: immunoassay (Diasorin) | COVID-19 and VD level: Q1: OR=1. Q2: OR=0.93, CI=0.67-1.28, P=0.65. Q3: OR=1.03, CI=0.74-1.44, P=0.84. Q4: OR=1.11, CI=0.79-1.56, P=0.54 | No significant association between VD level and COVID-19 risk. | Selection: *, comparability: ***, outcome: ***, Total: 6/10 (moderate quality) |
| Li et al[24]             | Preprint | Retrospective analysis | 1,746 patients with COVID-19, 399 deaths. Controls=494,034 | COVID-19 cases: 68.76 (±9.18), Controls: 68.44 (±8.11) | BMI: Cases: 27.53 (±4.88) kg/m², control: 27.42 (±4.79) kg/m² | VDD: 25(OH) D <25 nmol/L. Time: 2006-2010. Method: immunoassay (Diasorin) | VD level and mortality rate: 1.00 (0.99-1.01), P=0.687. (Multivariate analysis) | No significant association between VD level and COVID-19 risk and severity of symptoms | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| Raiser-Estabragh et al[27] | Retrospective analysis | 4510 participants (COVID-19 positive=1326, COVID-19 negative=3184) | COVID-19 positive: BMI=28.04 (± 6.47) kg/m², diabetes: 217 (16.4%), hypertension: 624 (47.1%). COVID-19 negative: BMI=27.41 (±6.37), diabetes: 449 (14.1%), hypertension: 1,457 (45.8%) | VDD: 25(OH) D <25 nmol/L. Time: 2006-2010. Method: immunoassay (Diasorin) | COVID-19 and VD level: OR 1.00 [1.00, 1.00], P=0.7185. (Multivariate analysis) | Risk of COVID-19 among men and BAME was not explained by vitamin D level. | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |

Contd...
| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n,%) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|------------------|---------------------|-----------------------------------------------|-----------|---------------------|----------------------|
| Kaufman et al.[14]       | Columbia (USA) | Retrospective population based analysis | 191779 with COVID-19 | Median: 54 years (40.4-64.7) | Not mentioned. | Normal: vit D ≥30 ng/mL, Insufficiency: 30 > Vit. D >20 ng/mL, Deficiency: Vit. D <20 ng/mL. Time: within the preceded one year. Method: chemiluminescent immunoassay (DiaSorin) or liquid chromatography/tandem mass spectrometry. | Vitamin D level and SARS-CoV-2 positivity: adjusted OR 0.984 per ng/mL increment, 95% CI: 0.983-0.986; P<0.001. The result was adjusted to race/ethnicity, gender, and latitude. Importantly, vitamin D level was adjusted for seasonality. | Strong inverse relationships between vitamin D level and positivity for SARS-CoV-2. | Selection: ***, comparability: *, outcome: ***, Total: 7/10 (moderate quality) |
| Israel et al.[29]       | Israel | large observational population study | 52405 with COVID-19, 524,050 matched control. Test: RT-PCR | Median: cases (32.00, 18.00-50.00), controls (32.00, 18.00-50.00) | Adjusted Clinical Group ACG comorbidity score (median [IQR]): Cases (0.44, 0.17-1.67), controls (0.44, 0.17-1.67). | VDD <30 nmol/L (equal to 12 ng/mL). Time: 2010-2019. Method: not documented | Vitamin D level <30 nmol/L and COVID-19: OR 1.27 (95% CI: 1.199-1.355, P value=0.000). Vitamin D level 30-50 nmol/L and COVID-19: OR 1.183 (95% CI: 1.118-1.251, P=0.000). (Multivariate analysis) | Significant association between VDD and COVID-19 risk. | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| Katz et al.[28]       | Florida (USA) | Cross-sectional study | 887 with COVID-19 | 35 (4%) were less than 18 years. | No demographic statistics | Not documented. Time: during the preceded five years. Method: not documented | VDD and COVID-19 positivity: OR=5.155, 95% CI: 3.974-6.688, P<0.001 (adjusted for age) | Significant association between VDD and COVID-19 risk | Selection: **, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| D’Avolio. et al.[30] | Switzerland | Retrospective cohort study | 107 (27 with COVID-19, 80 without COVID-19). Test: PCR | Median: 73 years (IQR 63-81) | The level of vitamin D was illustrated by median and interquartile range IQR. Time: within 7 weeks of PCR result. Method: liquid chromatography coupled with a tandem mass spectrometry (LC-MS/MS). | VD level and COVID-19 risk: P=0.004, No OR CI were documented. Data were displayed as (25th-75th percentiles, interquartile range (IQR)) | Contd... | Contd... |
| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|--------------------|-----------------------------------------------|----------|---------------------|----------------------|
| Smet et al. [13]         | Belgium | Retrospective observational study | 2903 (186 with COVID-19, 2717 diseased control). Test: PCR | Median: 69 (52-80) | Chronic lung disease: 28 (15.1%), coronary artery disease: 110 (59.1%), diabetes: 26 (14.0%) | VDD: 25(OH) D <20 ng/mL. Time: on admission. Method: liquid chromatography-tandem mass spectrometry | VDD in cases versus control: 109 (58.6%) vs 1227 (45.2%), \( P=0.05 \). VDD rates increased from 52.2% in stage 1 CT to 62.4% in stage 3 (\( P<0.05 \)). Confounding factors were dealt with by stratification. - VDD and mortality rate: adjusted OR: 1.09 (CI: 1.03-1.24), \( P=0.0014 \). (Multivariate analysis) | Results were stratified by age and gender but no adjustment for other confounders. | Selection: ***, comparability: *, outcome: **, Total: 7/9 (high quality) |
| Lau et al. [25]          | New Orleans | Retrospective cross sectional analysis | 20 patients (13 ICU patients, 7 floor patients) | 65.2±16.2 years | Hypertension: 15 (75.0%), diabetes: 7 (35.0%) | VDI: 25(OH) D of <30 ng/mL. Time: on admission. Method: immunoassay | ICU: 11 (84.6%) had VDI. Mean value: 19.2±10.8 ng/mL. Floor: 4 (57.1%) had VDI. Mean value: 29.8±13.3 ng/mL. \( P=0.29 \) | Vitamin D deficiency is prevalent in patients with severe COVID-19 | Selection: *, comparability: *, outcome: ***, Total: 5/10 (moderate quality) |
| Meltzer et al. [31]      | Chicago, USA | Retrospective cohort study | 489 patients were tested for COVID-19 and vitamin D. 71 patients (15%) were positive for COVID-19. 124 (25%) patients were likely deficient. | 49.2 (18.4) | Hypertension: 261 (53%), diabetes: 137 (28%), chronic pulmonary disease: 117 (24%), chronic kidney disease: 116 (24%), depression: 119 (24%). | 25(OH) D of <20 ng/mL. When combined with the treatment, the following definitions were used: - Likely Deficient: VDD and treatment not increased. - Likely sufficient: VD sufficient and treatment not decreased. Time: within one year. Method: not documented | 25(OH) D of <20 ng/mL. When combined with the treatment, the following definitions were used: - Likely Deficient: VDD and treatment not increased. - Likely sufficient: VD sufficient and treatment not decreased. Time: within one year. Method: not documented | Selection: ***, comparability: *, outcome: **, Total: 6/9 (moderate quality) |
Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|---------------------|-----------------------------------------------|----------|---------------------|------------------------|
| Pizinni et al[32] | Austria | A prospective multicenter observational study | 109 patients with COVID-19 (22 outpatient +87 hospitalised). Test: RT-PCR | Median: 58±14 | Cardiovascular disease: 44 (40%), endocrine diseases: 49 (45%), hypertension: 32 (29%), hypercholesterolemia: 24 (22%), type 2 diabetes mellitus: 20 (18%), Chronic kidney disease: 7 (6%) | VDD <30 nmol/L (equal to 12 ng/mL), VDI 30-50 nmol/L (equal to 1.2-20 ng/mL). Time: 8 weeks post onset of COVID-19. Method: not documented | Mean vitamin D level in mild COVID-19 versus severe COVID-19 (64±31 nmol/L vs. 50±24 nmol/L, P=0.116). | Low vitamin D level is prevalent among patients with COVID-19 but not significantly associated with poor outcomes. | Selection: **, comparability: *, outcome: ***, Total: 6/10 (moderate quality) |
| Caragnano et al[33] | Italy | Retrospective observational analysis | 42 patients with acute respiratory failure due to COVID-19 were admitted to the respiratory intermediate care unit (RICU), not requiring intubation or intensive ventilation. Test: RT-PCR | 65±13 | BMI: 28.5 (± 5) kg/m², Hypertension: 26 (61.9%), cardiovascular disease: 16 (38.1%), chronic kidney disease: 16 (38.1%), diabetes: 11 (26.2%) | Normal: vit D ≥30 ng/mL. Insufficiency: 30 >Vit. D>20 ng/mL. Moderate deficiency: 20 >Vit. D >10. Severe deficiency: <10 ng/mL. Time: within 12 hours of admission. Method: chemiluminescence immunoassay | Prevalence of hypovitaminosis (vit D <30 ng/mL) =34/42 (81%). -No OR, CI or P value was mentioned. | No significant association between VDD and severity of COVID-19. However, a significantly higher mortality rate among patients with severe VDD. | Selection: **, comparability: *, outcome: ***, Total: 6/10 (moderate quality) |
| Im et al[34] | South Korea | Prospective analysis | 200 patients (50 with COVID-19 and 150 without COVID-19. Test: PCR | COVID-19 positive: 52.2±20.7. Control: 52.4±20.2 | Not documented | VDD: 25(OH) D of <20 ng/dl. Time: within 7 days of admission. Method: liquid chromatography-tandem mass spectrometry | Prevalence of VDD: COVID-19 cases versus control: 38/50 (76.0%) vs 65/150 (43.3%). P=0.003. Prevalence of VDD in patients with COVID-19 requiring mechanical ventilation: 80% | Vitamin D insufficiency is prevalent in patients with severe COVID-19 | Selection: **, comparability: outcome: ***, Total: 5/10 (moderate quality) |

Contd...
| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|------------------|---------------------|---------------------------------------------|--------|---------------------|----------------------|
| Abrishami et al. [35]    | Iran    | Retrospective analysis | 73 patients with COVID-19. Test: RT-PCR | 55.18±14.98 years | Diabetes: 11 (15.1%), hypertension: 18 (24.7%), ischemic heart disease: 13 (17.8%), chronic kidney disease: 16 (21.9%), asthma/COPD: 7 (9.6%), | VDD: 25(OH) D <25 ng/mL. Time: within 3 days of initial CT scan. Method: immunoassay | Vitamin D level and severe lung involvement in COVID-19: (OR=0.96, 95% CI 0.93-0.98, P=0.04). Mean vitamin D level in survived versus deceased: 38.41±18.51 versus 13.83±12.53, P=0.001. COVID-19: VDD and mortality rate: OR 6.84 (1.55-30.19), P=0.01. (Multivariate analysis) | A significant association between vitamin D deficiency and severity of COVID-19 and mortality rate. | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
| Faul et al. [36]         | Ireland | Retrospective study | 33 patients with COVID-19 related pneumonia. Test: RT-PCR | ARDS: 60±15, No ARDS: 56±14 | None had cancer, diabetes, cardiovascular disease or received immunosuppressive therapy | VDD: 25(OH) <30 nmol/L (equal to 12 ng/mL). Time: at baseline. Method: not documented. | Hazard ratio for intubation in patients with VDD: 3.19 (1.05-9.7), P=0.03 | Low vitamin D level is associated with the severity of symptoms in patients with COVID-19. | Selection: -, comparability: *, outcome: ***, Total: 4/10 (low quality) |
| Karonova et al. [37]     | Russia  | Retrospective analysis | 80 hospitalized patients with COVID-19 pneumonia. | 53.2±15.7 | Obesity: 18 (22.5%), ischemic heart disease: 18 (22.5%), diabetes: 12 (15%) | VDD: 30 >Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: baseline. Method: chemiluminescence immunoassay | VDD and severity of symptoms (OR 5.0, [95% CI: 1.06-23.66]), VDD and fatality (OR 5.87, [95% CI: 0.72-48.04]). Obesity effect was adjusted. | A positive association between VDD and severity of symptoms of COVID-19 and mortality rate. | Selection: **, comparability: *, outcome: ***, Total: 6/10 (moderate quality) |
| Tort et al. [38]         | Mexico  | Cross sectional study | 172 hospitalised patients with COVID-19 | 51.44±14.21 | Not documented | VDD and deaths: 27 (77.1%), VDD and death: 8 (22.9%), normal vitamin D and death: 0 (0.0%), P value=0.256. Patients with vitamin D level of less than 8 ng/mL were 3.69 times risk of dying (P=0.001, CI: 1.62-8.37). | VDD is prevalent in patients hospitalized with COVID-19. A significant association between very low vitamin D levels (<8 ng/mL) and fatality from COVID-19. | Selection: **, comparability: **, outcome: ***, Total: 5/10 (moderate quality) |

Contd...
Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n.%) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|---------------------|---------------------------------|-----------|---------------------|----------------------|
| Radujkovic et al.[39]    | Germany | Prospective observational study | 185 patients with COVID-19 (93 hospitalized and 92 outpatients. Test: RT-PCR) | Median 60 (49-70) | Cardiovascular disease: 58 (31%), diabetes: 19 (10%), Chronic kidney disease: 8 (4%), chronic lung disease: 15 (8%), active or history of malignancy: 17 (9%) | VDD: <12 ng/mL. VDI: <20 ng/mL. Time: at admission. Method: immunoassay | VDD was associated with a higher risk of severe outcomes (invasive mechanical ventilation/death) and death (HR 6.12 and 14.73, respectively) (multivariate analysis) | A significant association between VDD and the severity of COVID-19 and mortality rate. | Selection: ***, comparability:***, outcome:***, Total: 8/10 (high quality) |
| Merzon et al.[40]        | Israel  | Population based retrospective analysis | 7,807 individuals (782 were tested positive for COVID-19, 7,025 were tested negative for COVID-19. Test: 2019-ncov Assay (Allplex™)| | COVID-19 positive: Obesity: 235 (30.05%), diabetes: 154 (19.6%), hypertension: 174 (22.25%), cardiovascular disease: 78 (9.97%), chronic lung disorder: 66 (8.44%), COVID-19 negative: Obesity: 1,900 (27.05%), diabetes: 1,578 (22.46%), hypertension: 1,962 (27.93%), cardiovascular disease: 1,172 (16.68%), chronic lung disorder: 935 (13.31%). | NVD: vit D ≥30 ng/mL. VDI: 30>Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: within 2 months prior to COVID-19 onset. (author was contacted) Method: chemiluminescence assay (DiaSorin) | low vitamin D (<30 ng/mL) and COVID-19: OR 1.50 (95 CI: 1.13-1.98), P=0.001 Low vitamin D (<30 ng/mL) and hospitalization rate in patients with COVID-19: OR 1.95 (95 CI: 0.99-4.78), P=0.056 (Multivariate analysis) | Low vitamin D level was an independent risk factor for COVID-19 infection. | Selection: *, comparability: ***, outcome:***, Total: 6/10 (moderate quality) |
| Macaya et al.[41]        | Spain   | Retrospective analysis | 80 patients with COVID-19. Test: RT-PCR | Severe COVID-19: 75 years (66-84). Non-severe COVID-19: 63 years (50-72) | Hypertension: 50 (62.5%), diabetes mellitus: 32 (40%), cardiac disease: 19 (23.8%), advanced chronic kidney disease: 26 (32.5%), obesity: 23 (28.8%), smoking: 13 (16.3%) | VDD: 25(OH)D of <20 ng/mL. Time: on admission or within 3 months prior to COVID-19 onset. Method: chemiluminescent immunoassay | VDD in severe versus non-severe COVID-19: 20 (65%) versus 24 (49%), P value=0.236. Multivariate analysis: the OR for VDD was 3.2 (95% CI: 0.9-11.4), P=0.070. | A significant association between VDD and severe outcomes in patients with COVID-19 who were under 67 years of age. No significant association was found in those who were older than 67 years old. | Selection: ***, comparability:***, outcome:***, Total: 7/10 (moderate quality) |
### Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n.%) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|---------------------|-----------------------------------------------|----------|---------------------|------------------------|
| Panagiotou et al.[42]    | UK      | Cross-sectional | 160 inpatients with COVID-19 (extended dataset per author); Intensive therapy unit: 43 patients, Non-ITU wards: 117. Test: PCR or radiological | ITU: 61.1±11.8, Non-ITU: 76.4±14.9 | ITU: Hypertension (24, 68.6%), Diabetes: (14,40%), Obesity: (9,25.7%). Non-ITU wards: Hypertension (32,40.5%), Diabetes: (24, 30.4%), Obesity: (5,6.3%) | VDI <50 nmol/L (equal to 20 ng/mL). Time: at admission. Method: immunoassay | ITU: prevalence of VDD was 35 (81.4%), VD level and mortality rate: OR 0.97 (95% CI: 0.42-2.23), P=0.94. | VDI is more common among patients admitted to ITU. No significant association between vitamin D level and mortality rate. | Selection: *, comparability: **, outcome: ***, Total: 6/10 (moderate quality) |
| Jain et al.[43]          | India   | Prospective observational study | 154 patients with COVID-19: 91 asymptomatic and 63 severe (admitted to ICU). Test: RT-PCR | Asymptomatic group: 42.34±6.41, Severe group: 51.41±9.12 | Patients with chronic obstructive airway disease; chronic kidney disease on dialysis, or on chemotherapy were excluded from the study. BMI: asymptomatic versus severe group: 27.23±4.5 kg/m² vs 26.83±5.81 | VDD: 25(OH) D of <20 ng/mL. Time: at diagnosis. Method: immunoassay | VDD in asymptomatic versus severe group: 29 (31.9%) vs 61 (60.5%). The fatality rate was 21% among patients with VDD. | VDD is more common among patients with severe COVID-19 and associated with a higher mortality rate. | Selection: ***, comparability: *, outcome: ***, Total: 7/10 (moderate quality) |
| Hernández et al.[44]     | Spain   | Case-control study | 216 patients with COVID-19 (19 of them were on vitamin D supplement and were excluded from the analysis). Control: 197. Test: RT-PCR | Cases versus control: 61.0 (47.5-70.0) vs 61.0 (56.0-66.0) | Cases versus control: BMI (29.2±4.7 vs 28.9±4.0), hypertension (76 (38.6%) vs 87 (44.2%), diabetes (34 (17.3%) vs 31 (15.7%), cardiovascular disease (21 (10.7%) vs 22 (11.2%). | VDD: 25(OH) D of <20 ng/mL. Time: at admission. Method: chemiluminescence assay | VDD and combined severity endpoints of COVID-19: adjusted OR 1.13, 95% CI 0.27-4.77; P=0.865. (Multivariate analysis) | No significant association between VDD and combined severity endpoints of COVID-19 | Selection: ***, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
| Maghbooli et al.[45]     | Iran    | Cross-sectional study | 235 hospitalized patients. RT-PCR or radiological | BMI (mean): 27.4±4.55 kg/m², diabetes: 36.6%, hypertension: 44.4%, immunological disorders: 1.3%, COPD: 1.3%, heart disorders: 22.1%, malignancy: 0.9%, lung disorders: 5.5%, asthma: 4.3% | BMI (mean): 27.4±4.55 kg/m², diabetes: 36.6%, hypertension: 44.4%, immunological disorders: 1.3%, COPD: 1.3%, heart disorders: 22.1%, malignancy: 0.9%, lung disorders: 5.5%, asthma: 4.3% | VDI: 25(OH) D of <30 ng/mL. Time: at admission. Method: electrochemiluminescence | Low vitamin D (<30 ng/mL) and severity of COVID-19: OR 1: 59, 95% CI: 1.05-2.41, P=0.02. Low vitamin D (<30 ng/mL) and mortality in patients with COVID-19: OR 1: 12, 95% CI: 1.0-1.26, P=0.04 (multivariate analysis) | A significant association between VDD and severity of symptoms and fatality from COVID-19. However, only 31.06% of recruited subjects had SARS-CoV-2 PCR testing. | Selection: ***, comparability: ***, outcome: ***, Total: 7/10 (moderate quality) |
Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|----------------------|-----------------------------------------------|----------|---------------------|----------------------|
| Luo et al[46]            | China   | Cross-sectional study | 335 hospitalised patients with COVID-19. Test: PCR | 56.0 years (IQR: 43.0-64.0) | Comorbidities: 147 (43.9%), BMI: 23.5±3.13, Smoking: 45 (13.4) | VDD: 25(OH) D of <30 nmol/L (equal to 12 ng/mL). Time: at admission. Method: chemiluminescence immunoassay | VDD and severe COVID-19 (OR: 2.72; 95% CI: 1.23-6.01, P value=0.014). (multivariate analysis) | Significant association between VDD and severity of COVID-19. | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
| Ye et al[47]             | China   | Case-control study | 62 patients with COVID-19 and 80 healthy controls (matched with cases by age and sex). Test: PCR | Median: 43 [32-59] | Diabetes: 5 (83.3%), hypertension: 6 (10.0%), liver injury: 1 (1.7%), COPD: 1 (1.7%), asthma: 0 (0.0%), renal failure: 16 (26.7%) | Normal: vit D ≥30 ng/mL. VDI: 30 >Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: at admission. Method: electro chemiluminescent immunoassay | VDD and severe/critical COVID-19: OR 5.18, 95% CI: 1.23-187.45, P=0.034) (multivariate analysis) | Significant association between VDD and severe/critical course of COVID-19 | Selection: ***, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
| Baktash et al[48]        | UK      | prospective cohort study | 105 patients: 70 patients were COVID-19 positive, 35 were COVID-19 negative. Test: RT-PCR | 81 years, range 65-102 | Hypertension: 34 (48.6%), diabetes: 26 (37.0%), ischemic heart disease: 15 (21.4%), chronic kidney disease: 16 (22.9%) | VDD: <30 nmol/L (12 ng/mL). Normal VD: ≥30 nmol/L (12 ng/mL). Time: at admission. | VDD and ventilatory requirement: RR: 4.15, 95%CI: 1.05-16.34, P=0.042. VDD and mortality rate: RR: 1.40, 95% CI: 0.36-5.47, P=0.50 | A significant association between VDD and severity of symptoms. No significant association between VDD and mortality rate. | Selection: ***, comparability: **, outcome: **, Total: 7/9 (high quality) |
| Mardani et al[49]        | Iran    | Cross sectional  | 123 patients: 63 patients were COVID-19 positive; 60 patients were COVID-19 negative. Test: RT-PCR | COVID-positive: 43.3 years, COVID-negative: 40.1 years. | Not documented | VDD: <10 ng/mL, VDI: 10-30 ng/mL, Normal VD: 30-100 ng/mL. Time: at admission. Method: enzyme-linked immunosorbent analysis (ELISA) | Mean vitamin D level in COVID-19-positive versus negative patients: 18.5 ng/dL vs. 30.2 ng/dL. | Patients with COVID-19 had low vitamin D levels, neutrophil to lymphocyte ratio (NLR), and high ACE levels. | Selection: ***, comparability: **, outcome: **, Total: 6/10 (moderate quality) |
| Arvinte et al[50]        | Colorado (USA) | Pilot study | 21 patients with COVID-19 in the ICU | Median: 61 years (20-94) | BMI: 31.6 (±7.3) kg/m², HbA1c: 7.6% (±2.0). | Definition: not documented. Time: at admission. | Mean vitamin D in overall sample: 22.0 (±9.5) ng/mL. Vitamin D level in survivors (n=11) versus non-survivor (n=10): 21.3 (±11.3) vs. 22.8 (±7.7) ng/mL, P=0.72. | Overall low level of vitamin D in most patients with COVID-19 | Selection: , comparability: **, outcome: ***, Total: 5/10 (moderate quality) |
Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|---------------------|-----------------------------------------------|-----------|-------------------|--------------------------|
| Ferrari et al. [51]      | Italy   | Retrospective analysis | 347 patients (128 COVID-19 positive, and 219 COVID-19 negatives. Test: RT-PCR) | COVID-19 positive: 65.0±15.0. COVID-19 negative: 58.7±20.2 | Not documented | Vitamin D level in patients with severe COVID-19 (death) versus non-severe COVID-19: (19.1±10.0 ng/mL vs. 22.2±16.6 ng/mL, P>0.05). Method: immunoassay | Vitamin D level in patients with severe COVID-19 (death) versus non-severe COVID-19: (19.1±10.0 ng/mL vs. 22.2±16.6 ng/mL, P>0.05). Method: immunoassay | No significant association between vitamin D level and COVID-19 risk and death | Selection: **, comparability: *, outcome: ***, Total: 6/10 (moderate quality) |
| Kerget et al. [52]       | Turkey  | Prospective observational study | 88 patients with COVID-19 and 20 patients without COVID-19 (control). Test: RT-PCR | Cases: 49.1±21.1. Control: 35.2±6.9 | Definition: not documented. Time: after admission. Method: enzyme-linked immunosorbent analysis (ELISA) | Vitamin D level in patients with COVID-19 who developed ARDS vs no ARDS: (16.8±10.5 vs. 21.8±5.8), Vitamin D level in patients with COVID-19 who died versus survived: (7.4±3 ng/mL vs. 21.1±14.2 ng/mL). | Vitamin D level was significantly lower in patients with severe COVID-19 compared to mild cases | Selection: ***, comparability: *, outcome: *, Total: 5/9 (moderate quality) |
| Cereda et al. [53]       | Italy   | Prospective observational cohort study | 129 hospitalized patients with COVID-19. Test: RT-PCR | Median: 77 (65.0-85.0) BMI: median 24.7(22.5-27.6) kg/m². diabetes: 39(30.7%), hypertension: 89 (70.1%), ischemic heart disease: 52 (40.9%), chronic kidney disease: 24 (18.9%), | NVD: vit. D ≥30 ng/mL. VDI: 30 > Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: within 48 hours of admission. Method: chemiluminescence immunoassay | NVD: vit. D ≥30 ng/mL. VDI: 30 > Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: within 48 hours of admission. Method: chemiluminescence immunoassay | No significant association between VDD and in-hospital mortality: 1.73 (1.11-2.69, P=0.016). (Multivariate analysis) | Selection: **** comparability: **, outcome: *, Total: 7/9 (high quality) |
| Vassiliou et al. [54]    | Greece  | Prospective observational study | 30 patients with COVID-19 admitted to the ICU. Test: RT-PCR | 65±11 | Hypertension: 15 (50%), diabetes: 5 (16.7%), dyslipidemia: 9 (30%), coronary artery disease: 4 (13.3%), asthma: 1 (3.3%), COPD: 1 (3.3%), smoking: 3 (10%) | NVD: vit D ≥30 ng/mL. VDI: 30 > Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: at admission. Method: electrochemiluminescence immunoassay (ECLIA) | NVD: vit D ≥30 ng/mL. VDI: 30 > Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: at admission. Method: electrochemiluminescence immunoassay (ECLIA) | Patients with low versus high vitamin D level and 28-ICU mortality: 5 (33%) vs. 0 (0.0%). | Selection: **, comparability: *, outcome: **, Total: 5/9 (moderate quality) |
### Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n, %) | Definition of VDD, time, and method of testing | OR, CI, P | Summary of findings | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|----------------------|---------------------------------------------|-----------|---------------------|------------------------|
| Abbodollahi et al[55]    | Iran    | Case-control study (matched) | Cases: 201 patients with COVID-19. Controls: 201 patients without COVID-19. Test: RT-PCR | Cases: 48 (±16.95). Controls: 46.34 (±13.5) | Cases versus controls: Diabetes 42 (20.89%) vs 19 (9.45%), heart failure and hypertension: 20 (9.95%) vs 15 (7.46%), respiratory infections: 14 (6.96%) vs 8 (39.80%) | NVD: vit. D ≥30 ng/mL. VDI: 30 >Vit. D >10 ng/mL. VDD: Vit. D <10 ng/mL. Time: at admission. Method: enzyme-linked immunosorbent assay method | Insufficient VD level in cases versus controls: 162 (80.5%) vs 132 (65.7%), P=0.001. | Low vitamin D level is prevalent in patients with COVID-19 | Selection: **, comparability: *, outcome: **, Total: 7/10 (moderate quality) |
| Anjum et al[56]          | Pakistan | Prospective observational study | 140 patients with COVID-19. Test: RT-PCR | 42±14.73. BMI: mean 23.48±3.62. Other comorbidities were not documented | VDD: 25(OH) D <25 nmol/L (equal to 10 ng/mL). Time: at admission. Method: not documented | Mortality rate in VDD versus non-VDD groups: 16 (26.67%) vs 6 (7.5%), P=0.02. | A significant association between severe VDD and mortality rate in patients with COVID-19 | Selection: **, comparability: *, outcome: *, Total: 4/9 (low quality) |
| Gonçalves et al[57]      | Brazil  | Cross-sectional study | 176 patients with COVID-19. Test: RT-PCR | 72.9±9.1 Hypertension: 127 (72.2), diabetes: 72 (40.9), heart disease: 48 (27.3), lung diseases: 48 (27.3) | VDD: 25(OH) D of <20 ng/mL. Time: at admission. Method: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) | Prevalence of VDD: 116 (65.9%). | VDD is prevalent in ICU patients with COVID-19 | Selection: **, comparability: **, outcome: ***, Total: 6/10 (moderate quality) |
| Karahan et al[58]        | Turkey  | Retrospective study | 149 hospitalized patients with COVID-19. Test: RT-PCR | 63.5±15.3 Diabetes: 61 (40.9%), hypertension: 85 (57.0%), coronary artery disease: 32 (21.5%), chronic kidney disease: 29 (19.5%). | NVD: vit. D ≥30 ng/mL. VDI: 30 >Vit. D >20 ng/mL. VDD: Vit. D <20 ng/mL. Time: not documented. Method: electrochemiluminescence method | Mean vitamin D level in severe-critical versus moderate cases: 10.1±6.2 vs. 26.3±8.4 ng/mL. VD level and mortality rate: OR 0.927 (CI: 0.875-0.982), P=0.010 (multivariate analysis) | A significant association between VDD and severity and mortality rate in patients with COVID-19 | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
| Ling et al[59]           | UK      | Cross-sectional study (multi-center) | 403 patients with COVID-19 in the primary analysis. Test: RT-PCR | Median: 74 (63-83) | VDD: 25(OH) D <25 nmol/L. Time: within 12 weeks prior to admission. Method: immunoassay | VDD and invasive mechanical ventilation: OR 2.73 (CI: 0.94-7.93), P=0.065. VDD and mortality rate: OR 0.80 (CI: 0.41-1.54), P=0.496 (multivariate analysis) | No significant association between vitamin D level and COVID-19 mortality. | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
### Table 1: Contd...

| Author and year of study | Country | Study design | Sample size | Age (mean, years) | Comorbidities (n.%)) | Definition of VDD, time, and method of testing | OR, CI, P                    | Summary of findings                                                                 | NOS quality assessment |
|--------------------------|---------|--------------|-------------|-------------------|----------------------|-----------------------------------------------|------------------------------|----------------------------------------------------------------------------------|-----------------------|
| Sun et al. [60]          | China   | Retrospective study | 241 patients with COVID-19, vitamin D testing was done in 26 patients only. Test: RT-PCR | Median: 65 (IQR, 55-72) | Not documented | Definition: not documented. Time: within 24 hours of admission. Method: not documented. | VD level: median 10.20 (IQR, 8.20-12.65) ng/mL. | Patients with COVID-19 had low vitamin D and serum calcium levels. | Selection: **, comparability: **, outcome: ***, Total: 5/10 (moderate quality) |
| Fanii et al. [61]        | UK      | Cross-sectional study | 392 health care workers (214 (55%) had seroconversion, 178 (45%) had no seroconversion. Test: serology | Median: 41 (30-50) | BMI: 25.9 (22.9-30.1) kg/m^2, one or more comorbidities: 152 (39%), hypertension: 34 (9%), asthma 26 (7%) | VDD <30 nmol/l (equal to 12 ng/mL). Time: at baseline. Method: mass spectrometry | VDD and positive seroconversion: OR 2.6, 95%CI 1.41-4.80; P=0.002 | VDD was an independent risk factor for the development of positive seroconversion of COVID-19 | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
| Pinzon et al. [26]       | Indonesia | Case series | 10 hospitalized patients with COVID-19. Test: either RT-PCR or serology | 49.6 years. | Hypertension: 4 (40.0%), diabetes: 1 (10.0%), COPD: 1 (10.0%), post stroke: 1 (10.0%) | NVD: vit. D ≥30 ng/mL. VDI: 30 >Vit. D ≥20 ng/mL. VDD: Vit. D <20 ng/mL. Time: not documented. Method: enzyme-linked immunosorbent assay method | VDD: 9/10 patients (90%). VDI: 1/10 patients (10%) | VDD is prevalent in patients with COVID-19 | Selection: **, comparability: **, outcome: ***, Total: 7/10 (moderate quality) |
overall validity of the results. Therefore, we decided to exclude this study from our analysis. The pooled analysis revealed a significant association between VDD/VDI and the severity of symptoms in patients with COVID-19 (OR = 3.38, 95% CI: 1.94–5.87, \( P < 0.0001 \)). Figure 3a shows the forest plot of VDD/VDI versus normal vitamin D and severity of symptoms of COVID-19 (composite outcomes).

Moderate heterogeneity was noted (\( I^2 = 67\% \)). On sensitivity analysis, three studies\(^{43,44,58} \) were the main reasons for heterogeneity, and the heterogeneity test (\( I^2 \) score) dropped to 12% (low level of heterogeneity) when these three studies were omitted from the analysis and the effect size was still significant (OR: 2.51, CI: 1.79–3.52, \( P \) value <0.00001).

Another pooled analysis revealed significantly lower mean
levels of vitamin D in patients with COVID-19 who had severe symptoms when compared to those with mild/ordinary outcomes (standardized mean difference: −6.85, CI: −9.43–−4.27, \(P\) value <0.00001, \(F\) = 96%). Figure 3b illustrates the pooled analysis of mean vitamin D level (ng/mL) and severity of symptoms of COVID-19.

Additional sub-analysis between VDD and individual outcomes revealed a significant association between VDD and mechanical ventilation (OR: 2.73, CI: 1.55–4.82, \(P\) value <0.001, \(F\) = 0%), radiological worsening (OR: 1.60, CI: 1.03–2.48, \(P\) value = 0.04, \(F\) = 0%), ICU admission (OR: 5.73, CI: 3.48–9.45, \(P\) value ≤ 0.001, \(F\) = 72%) and ARDS development (OR: 11.27, CI: 2.63–48.26, \(P\) value = 0.001, \(F\) = 1%). The forest plot of VDD/VDI versus normal vitamin D and severity of symptoms of COVID-19 (individual outcomes) can be found in the Supplementary Figure 1.

VDD/VDI and the case fatality rate in patients with COVID-19

Seventeen studies assessed the association between VDD/VDI and case fatality rate.  
\[13,34,35,37-44,46,48,51,54,56,58\] A significant association was observed between the pooled effects of VDD/VDI and case fatality rate (OR = 2.30, 95% CI: 1.47–3.59, \(P\) value <0.00001). Pooled analysis of VDD/VDI and case fatality rate in patients with COVID-19 is depicted in Figure 4. A moderate level of heterogeneity, although not significant, was noted (\(F\) = 36%, \(P\) value = 0.06). Notably, sensitivity analysis showed a persistently significant association between low vitamin D level and case fatality rate when two studies conducted by Jain et al. (2020)[43] and Karahan et al. (2020)[58] were omitted from the analysis (OR = 1.87, 95% CI: 1.27–2.76, \(P\) value = 0.002) and the heterogeneity test (\(F\)) dropped from 36% to 18%.

Figure 3: (a) Forest plot: Vitamin D deficiency/insufficiency versus normal vitamin D and severity of symptoms of COVID-19 (composite outcomes). (b) Pooled analysis of mean vitamin D level (ng/mL) and severity of symptoms of COVID-19.
Three,\textsuperscript{[15,28,40]} five,\textsuperscript{[37,41,44,46,59]} and four studies\textsuperscript{[35,37,53,59]} studies that adjusted for confounders were included in the pooled analysis of VDD and risk, the severity of symptoms, and mortality rate of patients with COVID-19, respectively. Pooled analysis of the adjusted OR can be found in Supplementary Figure 2a-c and revealed a significant association between VDD and COVID-19 risk (adjusted OR: 1.971, CI: 1.68–2.3, \(P\) value = 0.000), the severity of symptoms (adjusted OR: 2.673, CI: 1.62–4.41, \(P\) value = 0.000), and mortality rate (adjusted OR: 1.555, CI: 1.09–2.21, \(P\) value = 0.014). Notably, using a fixed-effect model in view of the small number of studies that adjusted for confounders makes inferences about the general population challenging.\textsuperscript{[22]}

Quality of studies

The quality of the included studies was limited by the following factors: i) with the exception of the studies conducted by Im et al.\textsuperscript{(2020)},\textsuperscript{[34]} Jain et al.\textsuperscript{(2020)},\textsuperscript{[43]} Cereda et al.\textsuperscript{(2020)},\textsuperscript{[53]} Vassiliou et al.\textsuperscript{(2020)},\textsuperscript{[54]} Bakshat et al.\textsuperscript{(2020)},\textsuperscript{[48]} Radujkovic et al.\textsuperscript{(2020)},\textsuperscript{[39]} Anjum et al.\textsuperscript{(2020)},\textsuperscript{[46]} Pizinni et al.\textsuperscript{(2020)},\textsuperscript{[41]} and Kerget et al.\textsuperscript{(2020)},\textsuperscript{[52]} all the included studies were of retrospective design; ii) in the majority of studies, it was not clear how subjects were invited and recruited, which therefore predisposed the findings to selection bias; iii) with the exception of studies conducted by Smet et al.\textsuperscript{(2020)},\textsuperscript{[13]} Kaufman et al.\textsuperscript{(2020)},\textsuperscript{[14]} Hastie et al.\textsuperscript{(2020)},\textsuperscript{[15,16]} Darling et al.\textsuperscript{(2020)},\textsuperscript{[23]} Li et al.\textsuperscript{(2020)},\textsuperscript{[24]} Raisi-Estabragh et al.\textsuperscript{(2020)},\textsuperscript{[27]} Katz et al.\textsuperscript{(2020)},\textsuperscript{[28]} Israel et al.\textsuperscript{(2020)},\textsuperscript{[29]} Meltzer et al.\textsuperscript{(2020)},\textsuperscript{[31]} Macaya et al.\textsuperscript{(2020)},\textsuperscript{[31]} Ye et al.\textsuperscript{(2020)},\textsuperscript{[47]} Hernández et al.\textsuperscript{(2020)},\textsuperscript{[44]} Cereda et al.\textsuperscript{(2020)},\textsuperscript{[53]} Radujkovic et al.\textsuperscript{(2020)},\textsuperscript{[39]} Luo et al.\textsuperscript{(2020)},\textsuperscript{[40]} Abrishami et al.\textsuperscript{(2020)},\textsuperscript{[35]} Merzon et al.\textsuperscript{(2020)},\textsuperscript{[30]} Karonova et al.\textsuperscript{(2020)},\textsuperscript{[37]} and Ling et al.\textsuperscript{(2020)},\textsuperscript{[59]} no adequate adjustment for confounding factors such as body mass index (BMI), comorbidities, and socioeconomic status was performed. A detailed quality assessment of the included studies is depicted in Table 1.

Publication bias

Egger’s regression intercept analysis was carried out for the two meta-analyses (severity of symptoms and case fatality rate). It revealed a non-significant risk of publication bias for the association between low vitamin D level and severity of symptoms (\(P\)-value: 0.071). However, the risk of publication bias was significant for the association between low vitamin D level and mortality rate (\(P\)-value: 0.023). Figure 5 illustrates the funnel plots and Egger’s regression intercept.

**Discussion**

The results of our meta-analysis support a high prevalence of VDD/VDI in patients with COVID-19. Besides, a significant association was illustrated between VDD/VDI and severity of symptoms and case fatality rate among patients with COVID-19.

The results of a meta-analysis by Zhou et al.\textsuperscript{(2019)}\textsuperscript{[62]} suggest an inverse correlation between VDD and the risk of development of community-acquired pneumonia (CAP),\textsuperscript{[62]} although one can argue that these findings cannot be generalized for infection caused by this novel coronavirus (SARS-CoV-2). Preliminary
Funnel plots and Egger’s regression intercept: A. VDD/VDI and severity of symptoms. B. VDD/VDI and mortality rate, in patients with COVID-19

Figure 5: Funnel plots and Egger’s regression intercept: A. VDD/VDI and severity of symptoms. B. VDD/VDI and mortality rate, in patients with COVID-19

Evidence from epidemiological studies published so far suggests an inverse correlation between vitamin D levels and risk of symptomatic COVID-19 infection. Another ecological analysis underlined the higher vulnerability to COVID-19 infection in populations with lower vitamin D levels. Low vitamin D levels were also observed to be an independent predictor of COVID-19 risk in multivariate analyses conducted by Meltzer et al. (2020) and Merzon et al. (2020) (relative risk [RR] = 1.77, P < 0.02) and Merzon et al. (2020) (OR: 1.50, P = 0.001). The possible mechanisms of such an association could be ascribed to the immunomodulatory role of vitamin D. Notably, individuals with low vitamin D levels have a reduced concentration of vitamin D receptors (VDRs) and antimicrobial peptides, which increases their susceptibility to bacterial and viral infections.

Our analysis identified a significant association between low vitamin D levels (VDD/VDI) and the severity of COVID-19 symptoms. Emerging evidence points toward the cytokine storm as the main drive for ARDS and a severe course of COVID-19. The cytokine storm involves the release of increased amounts of pro-inflammatory cytokines (interleukin IL-1β, IL-6, IL-12, interferon-γ) and chemokines (CXCL10 and CCL2), which trigger the systemic inflammatory response. Besides, being a potent immune modulator of different immune cells, vitamin D is associated with the down-regulation of some important cytokines, such as IL-6 and TNF-α, which play an essential role in the development of cytokine storm.

Therefore, low vitamin D levels impair the down-regulation of these inflammatory cytokines and potentially contribute to the development of ARDS. Vitamin D receptors are richly expressed in the lungs and shown to protect against sepsis-induced lung injury by inhibiting the angiotropin-2-TEK receptor tyrosine kinase-myosin light-chain kinase pathway. In animal models, 1,25 hydroxyvitamin D has been shown to attenuate lipopolysaccharide (LPS)-induced lung damage by modulating the renin-angiotensin system (RAS). Vitamin D has been shown to induce ACE2/angiotensin axis activity and increase the level of ACE2 in comparison to ACE1, which thereby attenuates angiotensin II-mediated vasoconstriction and lung injury.

Also, vitamin D promotes autophagy, which is an essential biological process in maintaining cellular hemostasis and enhancing the antiviral environment. Besides, some evidence suggests that vitamin D enhances the production of lung surfactants, which are essential in maintaining the integrity of alveolar–air interface and thereby gas exchange in the lungs. A summary of the postulated mechanisms of action of vitamin D on COVID 19 is depicted in Supplementary Figure 3.

The increased case-fatality in COVID-19 has been attributed to the development of ARDS due to a cytokine storm apart from a pro-thrombotic state. The mechanistic basis of the contribution of lower vitamin D levels to a pro-inflammatory and acute lung injury remains a plausible hypothesis. The results of our meta-analysis suggest a significant association between VDD/VDI and the case fatality rate in COVID-19 patients, which remains significant even after adjusting for some confounders. However, given the small sample sizes of the included observational studies that addressed the case-fatality rate and vitamin D status in patients with COVID-19 and the significant risk of publication bias, it is prudent to interpret these findings cautiously. Nonetheless, Ilie et al. (2020) found a negative correlation between the mean vitamin D level and mortality rate from COVID-19 in 20 European countries. Although most of the evidence related to VDD/VDI and case fatality rate in patients with COVID-19 is driven from ecological studies, these results are subject to the ecological fallacy and cannot, therefore, be applied on an individual level.

Implications

This systematic review will add supplementary evidence to the existing dataset about the relationship between vitamin D levels and viral respiratory illness. We believe that our meta-analysis comprehensively summarizes the available data on the relationship between VDD/VDI and the severity of COVID-19 symptoms and mortality rate. Considering the availability and safety of vitamin D supplements at the required doses, local guidelines need to be followed to prevent VDD. For example, the UK government advises all people to consider taking 10 micrograms (400 IU) of vitamin D supplements daily during the COVID-19 pandemic to maintain their musculoskeletal
health, especially if they spend most of their time indoors. However, it is debatable if such an approach will mitigate the severity of symptoms in patients with COVID-19 as perhaps a higher prophylactic dose of vitamin D is needed to provide immunomodulatory benefits.

Limitations
Our study is subject to several limitations. First, most of the studies included were retrospective observational designs that may impede the inference of a causal relationship. It was not clear whether low vitamin D level predisposes patients to an increased risk of severe COVID-19 or the low vitamin level is a consequence of COVID-19. However, applying Hill’s criteria to the causality reveals a consistent and strong association between VDD and COVID-19 severity. Also, the temporal precedence of vitamin D testing in several studies with the exception of one study in which testing was done at 8 weeks post-infection, increases the probability of the low vitamin D level being a factor in increasing the severity of COVID-19. Second, the SARS-CoV-2 positivity based on PCR testing in the large population-based studies is only considered as a precursor for COVID-19 disease and many people with a positive test do not develop the disease. Second, moderate heterogeneity was noted, which implies a cautious interpretation of our findings. However, the heterogeneity test (I²) dropped from 67% to 12% and the results were still statistically significant, when sensitivity analysis of the association between VDD/VDI and COVID-19 severity of symptoms was performed. Third, different cut-off values were used to define VDD, VDI, and normal vitamin D levels. However, we believe that the cut-off values used in this study had correctly combined the majority of studies. Fourth, a considerable number of studies lacked any adjustment for confounding factors, which might have influenced the overall results. Besides, the lack of the seasonality adjustment of vitamin D level in the majority of studies is an important factor that might have impacted our findings. However, a large population-based study substantiated a strong inverse association between vitamin D level and positivity for SARS-CoV-2 testing even after adjustment for seasonality effect on vitamin D level. Fifth, different criteria for the severity of symptoms were used, which might also affect our findings. However, a separate analysis of each severity outcome was done and revealed similar results [Supplementary Figure 1]. Sixth, the relatively small sample size of some studies might have overestimated the true association between vitamin D levels and COVID-19. Seventh, we acknowledge that the methods used for vitamin D testing might affect the accuracy of vitamin D levels across different studies. Eighth, only a few studies in this systematic review were population-based and the majority were conducted on hospitalized patients, which could inevitably affect the generalizability of our findings.

Future directions
Ongoing clinical trials should provide further clarity regarding these preliminary results, which suggest an inverse correlation between vitamin D levels and COVID-19 disease severity.

Conclusions
Vitamin D deficiency and/or insufficiency are relatively common in patients with COVID-19. A considerable amount of evidence indicates an inverse correlation between vitamin D levels and COVID-19 related clinical outcomes, including the case-fatality rate although most of the data so far have been derived from medium-quality observational studies. The ongoing, well-structured prospective clinical trials with a larger sample size should provide further evidence if prophylactic or therapeutic intervention with vitamin D improves COVID-19-related clinical outcomes.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8–28.
2. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: Modulator of the immune system. Curr Opin Pharmacol 2010;10:482–96.
3. Vanherwegem A, Gysemans S, Mathieu C. Regulation of immune function by vitamin D and its use in diseases of immunity. Endocrinol Metab Clin 2017;46:1061-94.
4. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012;88:2127-35.
5. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020;19:102537. doi: 10.1016/j.autrev.2020.102537.
6. Youssef DA, Miller CW, El‑Abbassi AM, Cutchins DC, Cutchins C, Grant WB, et al. Antimicrobial implications of vitamin D. Dermatoendocrinol 2011;3:220-9.
7. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of COVID-19? BMJ 2020;369:m1548.
8. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080S–6S.
9. Sizar O, Khare S, Goyal A, Bansal P, Givler A. Vitamin D Deficiency and mortality. Am J Clin Pathol 2021;155:381‑8.
10. Covid-19 Coronavirus Pandemic. Available from: https://www.worldometers.info/coronavirus/. [Last accessed on 2020 Jun 27].
11. Mercola J, Grant WB, Wagner CL. Evidence regarding vitamin D and risk of COVID-19 and its severity. Nutrients 2020;12:3361.
12. Laird E, Rhodes J, Kenny RA. Vitamin D and inflammation: Potential implications for severity of Covid-19. Ir Med J 2020;113:P81.
13. Smet DD, Smet KD, Herroelen P, Gryseerdt S, Martens GA. Serum 25(OH) D level on hospital admission associated with COVID-19 stage and mortality. Am J Clin Pathol 2021;155:381-8.
14. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One 2020;15:e0239252.
15. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020;14:561-5.
16. Hastie CE, Pell JP, Sattar N. Vitamin D and COVID-19 infection and mortality in UK Biobank. Eur J Nutr 2021;60:545-8.
17. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.
Al Kiyumi, et al.: Vitamin D deficiency and COVID-19

18. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.

19. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2012. Available from: http://wwwohrca/programs/clinical_epidemiology/oxfordasp.

20. Herzog R, Alvarez-Pasquin MJ, Díaz C, Barrio JLD, Estrada JM, Gil Á. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013;13:154.

21. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;20:5-13.

22. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97-111.

23. Darling LF, Ahmadi KR, Ward KA, Alves AC, Dunn-Walters DK, Lanham-New SA, et al. Vitamin D status, body mass index, ethnicity and COVID-19: Initial analysis of the first-reported UK Biobank COVID-19 positive cases (n=580) compared with negative controls (n=723). medRxiv 2020 preprint. doi: 10.1101/2020.04.29.20084277.

24. Li X, Geffen JV, Weele MV, Zhang X, He Y, Meng X, et al. Genetically-predicted vitamin D status, ambient UVB during the pandemic and COVID-19 risk in UK Biobank: Mendelian Randomisation study. medRxiv 2020 preprint. doi: 10.1101/2020.08.18.20177691.

25. Lau FH, Majumder R, Torabi R, Saeg F, Hoffman R, Cirillo JD, et al. Vitamin D insufficiency is prevalent in severe COVID-19. medRxiv 2020 preprint. doi: 10.1101/2020.04.24.20075838.

26. Pinzon RT, Angela A, Pradana AW. “Vitamin D deficiency among patients with covid-19: Case series and recent literature review”. Res Square 2020. doi: 10.21203/rs.3.rs-29473/v1.

27. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Pinzon RT, Angela A, Pradana AW. “Vitamin D deficiency among hospitalized patients in Tehran, Iran. J Med Virol 2021;93:2359-64.

28. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Pinzon RT, Angela A, Pradana AW. “Vitamin D deficiency as a predictor of poor prognosis to COVID-19 in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest 2021;44:765-71.

29. Darling AL, Ahmadi KR, Ward KA, Alves AC, Dunn-Walters DK, Lanham-New SA, et al. Vitamin D status: Study of 1326 cases from the UK Biobank. J Public Health 2020;42:451-60.

30. Katz J, Yue S, Yue W. Increased risk for Covid-19 in patients with Vitamin D deficiency. Nutrition 2020;84:111106.

31. Israel A, Cicurel A, Feldhamer I, Dror Y, Giveon SM, Gillis D, et al. Greater risk of severe COVID-19 in black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: Study of 1326 cases from the UK Biobank. J Public Health 2020;42:451-60.

32. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: A pilot study. Med Drug Discov 2020:8:100064.

33. Ferrari D, Locatelli M. No significant association between vitamin D and the modulation of the disease severity in COVID-19. Virus Res 2020;289:198148.

34. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: A pilot study. Med Drug Discov 2020:8:100064.

35. Mardani R, Alamdary A, Mousavi Nasab SD, Gholami R, Ahmadi N, Gholami A, et al. Association of vitamin D with the modulation of the disease severity in COVID-19. Virus Res 2020;289:198148.

36. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: A pilot study. Med Drug Discov 2020:8:100064.

37. Meltzer DO, Best TJ, Zhang H, Weele MV, Zhang X, He Y, et al. Association of vitamin D deficiency with COVID-19 risk in UK Biobank: Mendelian Randomisation study. J Clin Endocrinol Metab 2021;106:e1:343-53.

38. Vassiliou AG, Jahaj E, Pratikaki M, Orfanos SE, Dimopoulou I, et al. Vitamin D deficiency. Nutrition 2020;84:111106.

39. Radujkovic A, Hippenck T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 2020;12:2757.

40. Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: An Israeli population-based study. FEBS J 2020;287:3693-702.

41. Macaya F, Paeres CE, Valls A, Fernández-Ortiz A, Del Castillo JG, Martín-Sánchez J, et al. Interaction between age and vitamin D deficiency in severe COVID-19 infection. Nutr Hosp 2020;37:1039-42.

42. Anjum S, Suleman S, Afridi S, Yasmeen G, Kram Shah M, Afridi S. Vitamin D deficiency. Nutrition 2020;84:111106.

43. Jain A, Chaurasia R, Sengar NS, Singh M, Mohor S, Nairn S, et al. Association of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep 2020;10:1-8.

44. Ye K, Tang F, Liao X, Shaw BA, Deng M, Huang G, et al. Does serum vitamin D level affect COVID-19 infection and its severity?-A case-control study. J Am Coll Nutr 2020;1:8. doi: 10.1080/07315724.2020.1826005.

45. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van den Abbeele K, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J Epub 2021;97:442-7.

46. Mardani R, Alamdary A, Mousavi Nasab SD, Gholami R, Ahmadi N, Gholami A, et al. Association of vitamin D with the modulation of the disease severity in COVID-19. Virus Res 2020;289:198148.

47. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: A pilot study. Med Drug Discov 2020:8:100064.

48. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van den Abbeele K, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J Epub 2021;97:442-7.

49. Mardani R, Alamdary A, Mousavi Nasab SD, Gholami R, Ahmadi N, Gholami A, et al. Association of vitamin D with the modulation of the disease severity in COVID-19. Virus Res 2020;289:198148.

50. Arvinte C, Singh M, Marik PE. Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: A pilot study. Med Drug Discov 2020:8:100064.

51. Ferrari D, Locatelli M. No significant association between vitamin D and COVID-19. A retrospective study from a northern Italian hospital. Int J Nutr Res Rev 2020;1:4. doi: 10.1024/0300-9831/a000687.

52. Kerget B, Kerget F, Kuzliun G, Koçak AO, Araz O, Yılmazel Ücer E, et al. Evaluation of the relationship of serum vitamin D levels in COVID-19 patients with clinical course and prognosis. Tuberk Toraks 2020;68:227-35.

53. Cereda E, Bogliolo L, Klersy C, Lobascio F, Masi S, Crotti S, et al. Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clin Nutr 2021;40:2469-72.

54. Vassiliou AG, Jahai E, Pratikaki M, Orfano SE, Dimopoulos I, Kotanidou A. Low 25-hydroxyvitamin D levels on admission to the intensive care unit may predispose COVID-19 pneumonia patients to a higher 28-day mortality risk: A pilot study on a young ICU cohort. Nutrients 2020;12:3773.

55. Abdollahi A, Sarvestani HK, Rafat Z, Gaderkhani S, Gholami A, et al. Association between severe Vitamin D deficiency and mortality in patients with Covid-19. Pak J Med Health Sci 2020;14:1184-6.
57. Gonçalves TJM, Gonçalves SEAB, Guarnieri A, Risegato RC, Guimarães MP, de Freitas DC, et al. Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Nutr ESPEN 2020;40:110-4.
58. Karahan S, Katkat F. Impact of serum 25(OH) Vitamin D level on mortality in patients with COVID-19 in Turkey [published online ahead of print, 2020 Oct 5]. J Nutr Health Aging 2020;1-8. doi: 10.1007/s12603-020-1479-0.
59. Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, et al. High-Dose cholecalciferol booster Therapy is associated with a reduced risk of mortality in patients with COVID-19: A cross-sectional multi-centre observational study. Nutrients 2020;12:3799.
60. Sun JK, Zhang WH, Zou L, Liu Y, Li JJ, Kan XH, et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 2020;12:11287-95.
61. Faniyi AA, Lugg ST, Faustini SE, Webster C, Duffy JE, Hewison M, et al. Vitamin D status and seroconversion for COVID-19 in UK healthcare workers. Eur Respir J 2021;57:2004234.
62. Zhou YF, Luo BA, Qin LL. The association between vitamin d deficiency and community-acquired pneumonia. Medicine 2019;98:e17252.
63. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. Aging Clin Exp Res 2020;32:1609-12.
64. White JH. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: Past, present and future. J Steroid Biochem Mol Biol 2010;121:234-8.
65. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020;53:25-32.
66. Mohan M, Chelian JJ, Sharma A. Exploring links between vitamin D deficiency and COVID-19. PLoS Pathog 2020;16:e1008874.
67. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharideinduced acute lung injury via regulation of the reninangiotensin system. Mol Med Rep 2017;16:7432-8.
68. Mahdavi AM. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19. Rev Med Virol 2020;30:e2119.
69. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, et al. Mechanisms in endocrinology: Vitamin D and COVID-19. Eur J Endocrinol 2020;183:R133-47.
70. Phokela SS, Peleg S, Moya FR, Alcorn JL. Regulation of human pulmonary surfactant protein gene expression by 1alpha,25-dihydroxyvitamin D3. Am J Physiol Lung Cell Mol Physiol 2005;289:L617-26.
71. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32:1195-8.
72. NICE guidelines. Evidence review: Vitamin D for COVID-19. 2020. Available from: https://www.nice.org.uk/advice/es28/evidence. [Last accessed on 2020 Jun 18].
73. Hill AB. The environment and disease: Association or Causation? Proc R Soc Med 1965;58:295-300.
**Supplementary Figure 1:** Forest plot: Vitamin D deficiency/insufficiency versus normal vitamin D and severity of symptoms of COVID-19 (individual outcomes)
Supplementary Figure 2: Forest plot: Adjusted odds ratio: (a) VDD and COVID-19 risk. (b) VDD and severity of COVID-19. (c) VDD and mortality rate in patients with COVID-19.

Mechanisms of the action of vitamin D on COVID-19

- Regulation of innate as well as adaptive immunity by modulating the functioning of antigen presenting cells (macrophages, dendritic cells) and recruitment of T & B lymphocytes to site of infection.
- Macrophages maturation, generation of macrophages-specific surface antigens and lysosomal enzyme acid phosphatase.
- 1,25 hydroxy-vitamin D–vitamin D receptor complex enhance transcription of cathelicidin, which can block viral entry and replication.
- Promotion of autophagy, which is an essential biological process in maintaining cellular homeostasis and enhancing antiviral environment.
- Down-regulation of Interleukin-6 and Tumour Necrosis Factor-α (TNF-α), which play an important role in development of cytokine storm.
- Up-regulation of cathelicidin and β defensins, which are potent antimicrobial peptides.
- In animal models, Vitamin D has been shown to induce ACE2/Angiotensin (Ang) axis activity and inhibit renin and the ACE/Ang II cascade.

Supplementary Figure 3: Summary of the postulated mechanisms of the action of vitamin D on COVID-19